Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

‘Significant ongoing disruption’: DH issues two new SSPs for HRT

The Department of Health and Social Care (DH) has issued two new serious shortage protocols (SSPs) for hormone replacement therapy (HRT).

Estradot 50mcg and 100mcg patches are now on the list of SSPs due to “significant ongoing disruption” to supply, the Pharmaceutical Services Negotiating Committee (PSNC) announced yesterday (January 25).

Both SSPs were effective immediately as of yesterday and are currently set to expire on February 17, although they “may be amended or revoked at any time”, it said.

Under the new SSPs:

  • One Evorel 50mcg patch must be supplied for every Estradot 50mcg patch originally prescribed (SSP048)
  • One Evorel 100mcg patch must be supplied for every Estradot 100mcg patch originally prescribed (SSP049)

 

Do not double up strengths

 

However, the PSNC stressed that the two SSPs “do not allow pharmacists to double up strengths”, meaning they cannot supply two Estradot 25 patches against a prescription for one Estradot 50 patch for example.

The protocols also do not allow pharmacists to supply quantities covering less than the number of days originally prescribed and only allow substitution of Estradot patches for Evorel patches of the same strengths, it said.

There are no SSPs in place for other strengths of Estradot patches as they “are not affected by supply disruptions” and these should be “dispensed in accordance with the prescriptions”, it added.

Pharmacists should let the prescribing GP know when supplying medicines to a patient in accordance with SSPs and ensure that those “considered unsuitable for inclusion are promptly referred to their prescriber for further advice”, PSNC added.

“Pharmacists must exercise their professional judgement to ensure the alternative products are suitable for the patient,” it said.

 

Ongoing HRT supply issues

 

The new SSPs come after a brief reprieve in disruption last month, when six of the original 12 SSPs for HRT expired and pharmacists were able to resume dispensing products in line with prescriptions.

HRT products had been in and out of stock throughout last year, leading the DH to create a taskforce to deal with the ongoing crisis and supply issues.

In May, it issued 10 SSPs as part of the measures it introduced to alleviate HRT supply problems in the UK. The SSPs – which then rose to 12 – were further extended in July.

However, the HRT taskforce was disbanded in August, with the DH stating that access to HRT products had seen “a very substantial increase”.

But pharmacists C+D spoke to at the time said they were still struggling to access HRT products, as well as a host of other medicines.

Related Content

Topics

         
Pharmacy Manager / Pharmacist
Guernsey
£70,000

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD136725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel